Phosphorylation of β-arrestin 2 at Thr383 by MEK underlies β-arrestin-dependent activation of Erk1/2 by GPCRs
Abstract
In addition to their role in desensitization and internalization of G protein-coupled receptors (GPCRs), β-arrestins are essential scaffolds linking GPCRs to Erk1/2 signaling. However, their role in GPCR-operated Erk1/2 activation differs between GPCRs and the underlying mechanism remains poorly characterized. Here, we show that activation of serotonin 5-HT2C receptors, which engage Erk1/2 pathway via a β-arrestin-dependent mechanism, promotes MEK-dependent β-arrestin 2 phosphorylation at Thr383, a necessary step for Erk recruitment to the receptor/β-arrestin complex and Erk activation. Likewise, Thr383 phosphorylation is involved in β-arrestin-dependent Erk1/2 stimulation elicited by other GPCRs such as β2-adrenergic, FSH and CXCR4 receptors, but does not affect the β-arrestin-independent Erk1/2 activation by 5-HT4 receptor. Collectively, these data show that β-arrestin 2 phosphorylation at Thr383 underlies β-arrestin-dependent Erk1/2 activation by GPCRs.
Article and author information
Author details
Funding
Fondation pour la Recherche Médicale (Contract Equipe FRM 2009)
- Elisabeth Cassier
- Sylvie Claeysen
- Joël Bockaert
- Philippe Marin
- Franck Vandermoere
Agence Nationale de la Recherche (Contract ANR-2011-1619 01)
- Elisabeth Cassier
- Nathalie Gallay
- Thomas Bourquard
- Sylvie Claeysen
- Joël Bockaert
- Pascale Crépieux
- Anne Poupon
- Eric Reiter
- Philippe Marin
- Franck Vandermoere
Centre National de la Recherche Scientifique
- Elisabeth Cassier
- Sylvie Claeysen
- Joël Bockaert
- Philippe Marin
- Franck Vandermoere
Institut National de la Santé et de la Recherche Médicale
- Elisabeth Cassier
- Sylvie Claeysen
- Joël Bockaert
- Philippe Marin
- Franck Vandermoere
Université de Montpellier
- Elisabeth Cassier
- Sylvie Claeysen
- Joël Bockaert
- Philippe Marin
- Franck Vandermoere
Institut National de la Recherche Agronomique
- Nathalie Gallay
- Thomas Bourquard
- Pascale Crépieux
- Anne Poupon
- Eric Reiter
Université François-Rabelais
- Nathalie Gallay
- Thomas Bourquard
- Pascale Crépieux
- Anne Poupon
- Eric Reiter
The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.
Reviewing Editor
- Roger J Davis, University of Massachusetts Medical School, United States
Version history
- Received: November 29, 2016
- Accepted: February 6, 2017
- Accepted Manuscript published: February 7, 2017 (version 1)
- Version of Record published: February 24, 2017 (version 2)
Copyright
© 2017, Cassier et al.
This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.
Metrics
-
- 2,634
- views
-
- 586
- downloads
-
- 53
- citations
Views, downloads and citations are aggregated across all versions of this paper published by eLife.
Download links
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
Further reading
-
- Cell Biology
- Neuroscience
Alternative RNA splicing is an essential and dynamic process in neuronal differentiation and synapse maturation, and dysregulation of this process has been associated with neurodegenerative diseases. Recent studies have revealed the importance of RNA-binding proteins in the regulation of neuronal splicing programs. However, the molecular mechanisms involved in the control of these splicing regulators are still unclear. Here, we show that KIS, a kinase upregulated in the developmental brain, imposes a genome-wide alteration in exon usage during neuronal differentiation in mice. KIS contains a protein-recognition domain common to spliceosomal components and phosphorylates PTBP2, counteracting the role of this splicing factor in exon exclusion. At the molecular level, phosphorylation of unstructured domains within PTBP2 causes its dissociation from two co-regulators, Matrin3 and hnRNPM, and hinders the RNA-binding capability of the complex. Furthermore, KIS and PTBP2 display strong and opposing functional interactions in synaptic spine emergence and maturation. Taken together, our data uncover a post-translational control of splicing regulators that link transcriptional and alternative exon usage programs in neuronal development.
-
- Cell Biology
Amyotrophic lateral sclerosis (ALS) is a fatal neuromuscular disorder characterized by progressive weakness of almost all skeletal muscles, whereas extraocular muscles (EOMs) are comparatively spared. While hindlimb and diaphragm muscles of end-stage SOD1G93A (G93A) mice (a familial ALS mouse model) exhibit severe denervation and depletion of Pax7+satellite cells (SCs), we found that the pool of SCs and the integrity of neuromuscular junctions (NMJs) are maintained in EOMs. In cell sorting profiles, SCs derived from hindlimb and diaphragm muscles of G93A mice exhibit denervation-related activation, whereas SCs from EOMs of G93A mice display spontaneous (non-denervation-related) activation, similar to SCs from wild-type mice. Specifically, cultured EOM SCs contain more abundant transcripts of axon guidance molecules, including Cxcl12, along with more sustainable renewability than the diaphragm and hindlimb counterparts under differentiation pressure. In neuromuscular co-culture assays, AAV-delivery of Cxcl12 to G93A-hindlimb SC-derived myotubes enhances motor neuron axon extension and innervation, recapitulating the innervation capacity of EOM SC-derived myotubes. G93A mice fed with sodium butyrate (NaBu) supplementation exhibited less NMJ loss in hindlimb and diaphragm muscles. Additionally, SCs derived from G93A hindlimb and diaphragm muscles displayed elevated expression of Cxcl12 and improved renewability following NaBu treatment in vitro. Thus, the NaBu-induced transcriptomic changes resembling the patterns of EOM SCs may contribute to the beneficial effects observed in G93A mice. More broadly, the distinct transcriptomic profile of EOM SCs may offer novel therapeutic targets to slow progressive neuromuscular functional decay in ALS and provide possible ‘response biomarkers’ in pre-clinical and clinical studies.